Work

Interim results of a phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.14101

Authors: B. J. Dezube, R. Kurzrock, J. P. Eder, J. G. Supko, C. J. Meyer, L. H. Camacho, M. Andreeff, M. Konopleva, L. Lescale-Matys, D. Hong

Institutions: Beth Israel Deaconess Medical Center, The University of Texas MD Anderson Cancer Center, Reata Pharmaceuticals (United States), Massachusetts General Hospital, Dana-Farber Cancer Institute

Language: English

Topic: Natural product bioactivities and synthesis

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2267475740

Cites:

Cited by: 7

Related to: 10